株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性硬化症 : パイプライン製品の分析

Multiple Sclerosis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 232855
出版日 ページ情報 英文 780 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.52円で換算しております。
Back to Top
多発性硬化症 : パイプライン製品の分析 Multiple Sclerosis - Pipeline Review, H2 2017
出版日: 2017年12月21日 ページ情報: 英文 780 Pages
概要

多発性硬化症(MS)は、自身の免疫系が神経を覆う髄鞘(ミエリン)を攻撃する潜在的な消耗性疾患であり、ミエリンの損傷により、脳、脊髄、その他の部分の間のコミュニケーションが阻害されます。手足の麻痺、筋力低下、複視、霧視、刺痛または疼痛、疲労感、不明瞭発語などの症状があり、年齢、性別、家族歴、一部の感染症などが素因となります。

当レポートでは、世界における多発性硬化症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

多発性硬化症の概要

治療薬の開発

  • 多発性硬化症向けパイプライン製品:概要
  • 多発性硬化症向けパイプライン製品:比較分析

多発性硬化症:開発中の治療薬:企業別

多発性硬化症:開発中の治療薬:大学・研究機関別

多発性硬化症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

多発性硬化症:開発中の製品:企業別

多発性硬化症:開発中の製品:大学・研究機関別

多発性硬化症:治療薬開発に従事している企業

多発性硬化症:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 製品概要
  • 作用機序
  • R&Dの進捗

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

目次
Product Code: GMDHC9958IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 27, 29, 161, 35 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 4 and 48 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Sclerosis - Overview
  • Multiple Sclerosis - Therapeutics Development
  • Multiple Sclerosis - Therapeutics Assessment
  • Multiple Sclerosis - Companies Involved in Therapeutics Development
  • Multiple Sclerosis - Drug Profiles
  • Multiple Sclerosis - Dormant Projects
  • Multiple Sclerosis - Discontinued Products
  • Multiple Sclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Sclerosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2017
  • Multiple Sclerosis - Pipeline by 4D Pharma PLC, H2 2017
  • Multiple Sclerosis - Pipeline by AB Science SA, H2 2017
  • Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2017
  • Multiple Sclerosis - Pipeline by Abion Inc, H2 2017
  • Multiple Sclerosis - Pipeline by Ablynx NV, H2 2017
  • Multiple Sclerosis - Pipeline by Abzena Plc, H2 2017
  • Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H2 2017
  • Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2 2017
  • Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2 2017
  • Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2017
  • Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2 2017
  • Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2017
  • Multiple Sclerosis - Pipeline by Allergan Plc, H2 2017
  • Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2017
  • Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2 2017
  • Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2017
  • Multiple Sclerosis - Pipeline by Antoxis Ltd, H2 2017

List of Figures

  • Number of Products under Development for Multiple Sclerosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top